Motif ? one of the clinical technology market's fastest-growing companies ? today announced a multi-phase deployment of MotifAI Assistant, its AI-driven automation, across its product portfolio.

Mechelen, Belgium; November 3, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the ...

Experts at the 2025 OCT DACH conference will dive into the potential of the European region amid a shifting clinical trial ...

Pharmacists are integral to oncology care, optimizing treatment plans, managing adverse effects, and supporting precision medicine through collaborative practice agreements.

Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, ...

Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an ...

Tamara Murdock, global head of early phase at Emerald Clinical Trials emphasises the importance for sponsors in choosing the ...

According to Mordor Intelligence, the global clinical trials market is valued at USD 90.1 billion in 2025 and is projected to ...

Comprehensive CNS-Focused Services The center provides end-to-end support including CNS-specific protocol design, regulatory ...

| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts Next-generation Hydrocortisone Acetate (ngHCA™) Suppository Administered with Sephure® Suppos ...